Navigation Links
Pathway Medical Technologies Names Paul Buckman Chairman of the Board of Directors

KIRKLAND, Wash., March 6 /PRNewswire/ -- Pathway Medical Technologies, which is developing innovative medical devices for the treatment of arterial disease, announced that Paul Buckman has been named as the new Chairman of the Board of Directors. He replaces Dan Galles, who has been acting Board Chairman since late 2006.

"We are very pleased Paul has accepted the role of Chairman. He brings an extensive range of industry experience to the Pathway board, including early commercialization experience. This is especially important to the company as it prepares for the launch of its first product, the Pathway PV(TM) Artherectomy System," said Galles.

"Since Paul joined our Board in 2007, he has become a real asset. His deep commercial experience with a variety of companies has already proven useful," said Tom Clement, Pathway President and CEO, "and I expect in his new role, Paul's vision and leadership will continue to benefit both the company and the patients who will be treated with our device."

Buckman, who has worked in the medical device industry for over 30 years, is currently CEO and a director of Devax, Inc., a development-stage cardiovascular device company. He joined Devax in 2006 from St. Jude Medical, Inc. where he was an executive officer and President of its Cardiology Division. Before St. Jude Medical, Buckman served as Chairman of the Board of Directors and CEO of ev3, LLC, which he co-founded. Earlier in his career he was with Boston Scientific Corporation, where he held several executive positions before being named President of the Scimed Division, a post he held for 10 years. In the course of his career, Buckman has served on the Board of a variety of companies, including: EndiCor, Inc., Microvena, Inc., Micro Therapeutics, Inc., and Velocimed, Inc., which he also co-founded.

About Pathway Medical Technologies, Inc.

Pathway Medical Technologies, Inc. was founded to design, market and manufacture medical devices for the treatment of arterial disease. The company's initial focus is treating peripheral arterial disease (PAD) more quickly, safely and effectively than existing technologies. An estimated 8-12 million people are afflicted by PAD in the U.S., and that number is projected to grow to over 20 million during the next 10 years. The company's Pathway PV(TM) Atherectomy System allows for a minimally invasive procedure designed to restore circulation in the peripheral arteries by removing both hard and soft diseased tissue. For further information, visit the company's Web site at

SOURCE Pathway Medical Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Genetic pathway critical to disease, aging found
2. AspenBio Pharma Pursues FDA 510(k) Application Pathway for Appendicitis Blood Test
3. Pathway Diagnostics Announces Patent Issuance for the Diagnostic Measurement of HIV Tropism for the Initiation or Modification of HIV Therapy
4. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
5. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
6. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
7. Major Medical Journal Reports Higher Success, Fewer Complications and Lower Cost Treating DVT With Trellis(R) Isolated Thrombolysis Compared With Catheter-Directed Thrombolysis
8. Vista Partners Updates Coverage on Inovio Biomedical Corporation (Amex: INO) With $3.52 Price Target
9. LifeNet Health(R) Unveils New Biomedical Spine Implant
10. IMPAC Medical Systems and Aperio to Develop Integrated Solution for Anatomic Pathology
11. M. Scott Harris, M.D., Joins Ocera Therapeutics, Inc., as Chief Medical Officer
Post Your Comments:
(Date:11/25/2015)... , November 25, 2015 ... Report is a professional and in-depth study on ...      (Logo: ) , ... the industry including definitions, classifications, applications and industry ... for the international markets including development trends, competitive ...
(Date:11/24/2015)... -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting ... on Wednesday, December 2 at 9:30 a.m. ET/6:30 a.m. ... will provide a corporate overview. th Annual Oppenheimer ... p.m. ET/10:00 a.m. PT . Jim Mazzola , vice ... overview. --> th Annual Oppenheimer Healthcare Conference in ...
(Date:11/24/2015)... , Nov. 24, 2015  Clintrax Global, Inc., a worldwide provider ... , today announced that the company has set a new ... 391% quarter on quarter growth posted for Q3 of 2014 to ... and Mexico , with the establishment of an ... 2015. --> United Kingdom and ...
(Date:11/24/2015)... 2015 --> ... released by Transparency Market Research, the global non-invasive prenatal ... of 17.5% during the period between 2014 and 2022. ... Industry Analysis, Size, Volume, Share, Growth, Trends and Forecast ... market to reach a valuation of US$2.38 bn by ...
Breaking Biology Technology:
(Date:11/17/2015)... PARIS , November 17, 2015 ... 17 au 19 novembre  2015.  --> Paris ... 2015.  --> DERMALOG, le leader de l,innovation ... à la fois passeports et empreintes sur la même ... pour les passeports et l,autre pour les empreintes digitales. ...
(Date:11/12/2015)... 2015  A golden retriever that stayed healthy despite ... has provided a new lead for treating this muscle-wasting ... Institute of MIT and Harvard and the University of ... Cell, pinpoints a protective gene that ... effects. The Boston Children,s lab of Lou Kunkel ...
(Date:11/10/2015)... LONDON , Nov. 10, 2015 /PRNewswire/ ... segmented on the basis of product, type, ... segments included in this report are consumables, ... this report are safety biomarkers, efficacy biomarkers, ... in this report are diagnostics development, drug ...
Breaking Biology News(10 mins):